-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Qilu Pharmaceutical entered the administrative examination and approval stage with imtricitabine tenofovir tablets, which were submitted for production in the generic category 4, and is expected to be approved in the near future.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
Emtricitabine tenofovir tablet is a compound preparation of emtricitabine and tenofovir disoproxil fumarate.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
According to data from Menet.
com, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
com, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
Source: One-click search on Mi Nei.
com
com
Currently, emtricitabine, tenofovir tablets in the domestic market, production enterprises have four, which CTTQ Pharmaceutical Group, Anhui Baker biological, Hai Sike Pharmaceutical (Meishan) 3 domestic companies are based on the generic class won 4 Approval is regarded as over-comment.
In addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
In addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, Qilu Pharmaceutical entered the administrative examination and approval stage with imtricitabine tenofovir tablets, which were submitted for production in the generic category 4, and is expected to be approved in the near future.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
Emtricitabine tenofovir tablet is a compound preparation of emtricitabine and tenofovir disoproxil fumarate.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
According to data from Menet.
com, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
com, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
Source: One-click search on Mi Nei.
com
com
Currently, emtricitabine, tenofovir tablets in the domestic market, production enterprises have four, which CTTQ Pharmaceutical Group, Anhui Baker biological, Hai Sike Pharmaceutical (Meishan) 3 domestic companies are based on the generic class won 4 Approval is regarded as over-comment.
In addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
In addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, Qilu Pharmaceutical entered the administrative examination and approval stage with imtricitabine tenofovir tablets, which were submitted for production in the generic category 4, and is expected to be approved in the near future.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
According to data from Meinnet.
com, in recent years, the global sales of Gilead's emtricitabine tenofovir tablets have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and "halved" to US$1.
448 billion in 2020.
Emtricitabine tenofovir tablet is a compound preparation of emtricitabine and tenofovir disoproxil fumarate.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
It was developed by Gilead under the trade name Truvada.
It was launched in the United States in 2004.
According to data from Menet.
com, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
Hospital hospital hospitalcom, in recent years, Gilead’s global sales of emtricitabine tenofovir have gradually declined, from US$3.
566 billion in 2016 to US$2.
813 billion in 2019, and “cut in half” to US$1.
448 billion in 2020.
The sales of terminal emtricitabine tenofovir tablets in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly.
Although less than 50 million yuan in 2019, it was year-on-year The growth rate is as high as 86.
59%, with a year-on-year growth of more than 15% in the first half of 2020.
Source: One-click search on Mi Nei.
com
com
Currently, emtricitabine, tenofovir tablets in the domestic market, production enterprises have four, which CTTQ Pharmaceutical Group, Anhui Baker biological, Hai Sike Pharmaceutical (Meishan) 3 domestic companies are based on the generic class won 4 Approval is regarded as over-comment.
In addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
Enterprise business enterpriseIn addition, Shanghai Desano's application for the listing of tenofovir tablets for emtricitabine is under review and approval.
Qilu Pharmaceutical's registration status for this product has been changed to "under review" and will become the fourth domestic company after approval.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
